

1

2

Orthopoxvirus-specific antibodies wane to undetectable

3

levels one year after MVA-BN vaccination of at-risk

4

individuals

5

6 Leanne P. M. van Leeuwen^{1,2,*}, Marc C. Shamier^{1,*}, Babs E. Verstrepen¹, Hannelore M.
7 Götz³, Katharina S. Schmitz¹, Najlae Akhiyate¹, Koen Wijnans¹, Susanne Bogers¹, Martin E.
8 van Royen⁴, Eric C. M. van Gorp^{1,2}, Marion P. G. Koopmans¹, Rory D. de Vries^{1,#}, Corine H.
9 GeurtsvanKessel^{1,#}, Luca M. Zaack^{1,\$}

10

11 ¹ Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands

12 ² Travel Clinic, Erasmus University Medical Center Rotterdam, the Netherlands

13 ³ Department Infectious Disease Control, Municipal Public Health Service Rotterdam–Rijnmond (GGD
14 Rotterdam-Rijnmond), Rotterdam, the Netherlands

15 ⁴ Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands

16 * Equal first author contribution

17 # Equal senior author contribution

18 \$ corresponding author: Luca M. Zaack, Department of Viroscience, Erasmus University
19 Medical Center, 3015GD Rotterdam, the Netherlands, l.zaack@erasmusmc.nl

20

21

22

23

24

25 Abstract

26 In response to the 2022-2023 mpox outbreak, widespread vaccination with modified vaccinia
27 Ankara-Bavarian Nordic was initiated. Here, we demonstrate that orthopoxvirus-specific
28 binding and MVA-neutralizing antibodies wane to undetectable levels one year post-
29 vaccination in at-risk individuals without pre-existing immunity. Continuous surveillance is
30 essential to understand the impact of declining antibody levels.

31 **Introduction**

32 Since the beginning of the 2022-2023 global mpox outbreak, over 97,000 cases were
33 reported in 117 countries, including in previously non-endemic regions [1]. The vast majority
34 of monkeypox virus (MPXV) infections outside endemic regions were diagnosed in sexually
35 active gay, bisexual, or other men who have sex with men (GBMSM). To control the
36 outbreak, many countries initiated vaccination campaigns using the third-generation
37 smallpox vaccine modified vaccinia Ankara – Bavarian Nordic (MVA-BN). In the initial
38 months after the start of vaccination, studies on vaccine effectiveness (VE) yielded an
39 estimated aggregate VE of 82% (CI: 65%-89%) after two doses [2]. Breakthrough infections
40 after vaccination have been reported [3]. Combined, this raises questions on the long-term
41 effectiveness of MVA-BN against mpox.

42

43 We have previously shown that a two-dose MVA-BN vaccination regimen is immunogenic in
44 individuals without pre-existing immunity; vaccination resulted in the production of VACV
45 (vaccinia virus)-reactive binding antibodies, MVA-neutralizing antibodies (nAbs), and MPXV
46 nAbs one month after the second dose. However, the levels of MPXV nAbs were low
47 compared to those after historic smallpox vaccination, or after MPXV infection [4]. Little is
48 known about the durability of humoral immune responses, and the correlation between
49 waning antibody responses and long-term effectiveness of MVA-BN vaccination. While
50 antibodies induced by historic smallpox vaccination using first- or second-generation
51 vaccines can be detected for decades [5], prior studies into the longevity of orthopoxvirus-
52 specific antibodies after MVA-BN vaccination indicate that antibodies wane in vaccine
53 recipients without pre-existing immunity [6-10].

54

55 In this study, we specifically investigated the durability of orthopoxvirus-specific antibody
56 responses and report the longitudinal antibody dynamics up to 418 days after MVA-BN
57 vaccination in two risk groups, namely GBMSM and laboratory workers.

58 **Methods**

59 Sera from two biobank protocols were used. Both protocols were approved by the Erasmus
60 MC Medical Ethics Review Committee: the COVA study (MEC-2014-398) and the RestPlus
61 study (MEC-2022-0675) (**Supplementary Methods** and **Supplementary Figure S1**).
62 Written informed consent was obtained from all COVA study participants. Baseline
63 characteristics are documented in **Supplementary Table S1**.

64

65 In the COVA study, sera were collected from both high-risk GBMSM (N=99) and laboratory
66 workers (N=19). Laboratory workers were vaccinated as part of occupational safety
67 measures. Samples were obtained before and after MVA-BN vaccination (V0=baseline;
68 V1=14 days after first dose; V2=28 days after first dose; V3=28 days after second dose;
69 V4=1 year follow-up) (**Supplementary Table S2A**). Participants were vaccinated according
70 to the prescribed vaccination regimen: two subcutaneous doses with an interval of four
71 weeks for individuals who had not received historic smallpox vaccination. This included
72 participants born after 1974 (cessation of smallpox vaccination in the Netherlands), and
73 those born before 1974 with unclear vaccination history. Laboratory workers received two
74 doses of MVA-BN regardless of vaccination history. Other individuals who declared having
75 received historic smallpox vaccination received one MVA-BN dose. In the RestPlus study,
76 residual pseudonymized sera obtained in September 2022 from GBMSM attending the
77 Center for Sexual Health (CSH) in Rotterdam were screened for the presence of VACV-
78 specific binding antibodies [11]. In case of a positive result, all sera from that individual
79 collected between January 2022 and September 2023 were tested, and data were linked to
80 available vaccination- and/or infection data. Individuals without registration of an
81 administered MVA-BN vaccine, or without a positive MPXV PCR, were excluded from further
82 analysis. Longitudinal sera from N=116 individuals were eligible for analysis.

83

84 We measured VACV-specific binding antibody levels using an in-house ELISA in both
85 cohorts. For sera obtained from the COVA cohort, MVA nAb levels were measured by
86 plaque reduction neutralization test (PRNT). Both assays were performed as previously
87 described [4] (**Supplementary Methods**).

88 Results

89 In total, we analyzed sera from 234 participants enrolled in two different studies. Of the 99
90 GBMSM and 19 laboratory workers enrolled in the COVA study, 17 participants received
91 one dose and 101 participants received two doses of MVA-BN (**Supplementary Figure S1**
92 and **Supplementary Table S1**). As expected, no VACV-specific binding antibodies were
93 detected at baseline in either GBMSM or laboratory workers born after 1974 (**Figure 1A**).
94 Binding antibody levels gradually increased over time with detectable antibodies in all sera
95 (58/58; 100%) collected four weeks post-2nd dose (GMT 160 [95% CI 116-220]). However,
96 only 7/21 (33%) participants had detectable VACV-specific binding antibody levels above the
97 lower limit of detection (LLoD) at one year post-2nd dose (GMT 15 [95% CI 11-21]). We did
98 not observe a difference in binding antibody kinetics post-vaccination between GBMSM and
99 laboratory workers (**Supplementary Figure S2**).

100

101 In individuals born before 1974, VACV-specific binding antibodies were detected at baseline
102 before MVA-BN vaccination in 28/33 participants (85%) (**Figure 1B** and **Supplementary**
103 **Table S2B**). Binding antibody levels were boosted by the first dose of MVA-BN (GMT 897
104 [95% CI 347-2,324] for those receiving one dose, and GMT 675 [95% CI 166-2,742] for
105 those receiving two doses) at 28 days after first vaccination. A second dose of MVA-BN did
106 not result in an additional increase of binding antibody levels (GMT 949 [95% CI 347-2,596]
107 at 28 days after second vaccination; **Figure 1B**). Binding antibody levels in MVA-BN-
108 vaccinated participants with prior immunity remained stable at the one-year follow-up. Two
109 participants consistently had low or undetectable antibody levels.

110

111 To assess the durability of antibody functionality, we measured MVA nAbs in participants of
112 the COVA study. In participants born after 1974, we detected MVA nAbs in 41/51 (80%)
113 study participants 28 days after the second MVA-BN vaccination (GMT 39 [95% CI 31-51]),
114 compared to only 3/20 (15%) participants one year post-vaccination (GMT 11 [95% CI 9.8-
115 13]) (**Figure 1C**). In participants born before 1974, MVA nAbs were boosted by the first dose
116 of MVA-BN, without an additional increase after the second dose, comparable to binding
117 antibodies (**Figure 1D**). One year post-vaccination, MVA nAb levels waned, with 5/15 (33%)
118 individuals having MVA nAb levels below the LLoD.

119

120 Antibody kinetics were additionally studied up to 418 days post-vaccination in longitudinal
121 serum samples obtained from 116 GBMSM clients of the Rotterdam CSH, who received
122 MVA-BN vaccination (N=100) or had a positive MPXV PCR (N=6) (RestPlus study)
123 (**Supplementary Table S2C**). The vaccinated participants were grouped based on the
124 absence or presence of VACV-specific binding antibodies on the day of MVA-BN vaccination

125 into a baseline-negative (**Figure 1E** [one dose]; **Figure 1F** [two doses]) and a baseline-
126 positive (**Figure 1G**) group. Independent of the status at baseline, all groups showed an
127 increase in binding antibody levels post-vaccination, which peaked within 30-90 days.
128 Subsequently, binding antibody levels began to decline across all groups, returning close to
129 their respective baseline levels one year post-vaccination. For baseline-negative study
130 participants, among those who were followed-up for a year or longer, 65% (22/34) had low
131 (<20) to no detectable antibodies at the end of the study, whereas baseline-positive
132 individuals returned to their original baseline levels. Overall, this longitudinal cohort mirrored
133 antibody kinetics observed in the COVA study.

134

135 In the cohort of GBMSM clients of the Rotterdam CSH, there were six participants with a
136 PCR-confirmed mpox during the study period, all born after 1974 (**Figure 1H**). For two of
137 these individuals, only a single serum sample was available. One participant was diagnosed
138 with an MPXV infection in October 2022, following the completion of a double-dose MVA-BN
139 vaccination regimen in early September 2022 (**Figure 1H**, purple line). Comparison of
140 binding antibody levels shortly before and one month after infection revealed an increase
141 from 50 to 1807. Based on the binding antibody kinetics and magnitude, we suspect an
142 additional undetected infection among one of the participants after two doses of MVA-BN
143 (**Figure 1G**, red line). However, no clinical information and/or confirmatory PCR-tests were
144 available for this participant.

145 **Discussion**

146 Here, we showed that MVA-BN vaccination induced binding and MVA neutralizing
147 antibodies in previously unvaccinated at-risk study participants (born ≥ 1974), and that
148 vaccination boosts binding antibody levels in historically vaccinated at-risk individuals (born
149 < 1974). Binding and neutralizing antibody levels in non-primed at-risk individuals declined
150 rapidly at one year follow-up, and became undetectable in a considerable proportion of
151 cases.

152

153 Measuring the immunogenicity of MVA-BN is crucial for understanding the impact of
154 immunization strategies and supporting VE studies. Previous reports on long-term humoral
155 immunogenicity align with our findings [6-10]. However, we expand on them by providing
156 longitudinal immunological follow-up of over one year in those directly at-risk of clade IIb
157 MPXV infection. While the implications of low to absent antibody levels one-year post
158 vaccination remain unclear due to the absence of a clearly defined correlate of protection,
159 waning antibody levels raise the important question whether these individuals are still
160 protected and if this could possibly facilitate mpox resurgence.

161

162 In our study, we observed one confirmed and one suspected breakthrough infection, both
163 associated with an increase in binding antibody levels. Breakthrough infections after MVA-
164 BN vaccination have been previously reported and appear to result in a milder clinical profile
165 [3]. Explanations for breakthrough infections shortly after vaccination could be due to
166 antigenic differences between MVA and MPXV that result in suboptimal cross-reactivity, or
167 the potential absence of immunity at mucosal sites, a point of entry for clade IIb MPXV [4-
168 10].

169

170 We demonstrate a rapid decline in binding and neutralizing antibodies one-year after MVA-
171 BN vaccination in non-primed at-risk individuals. Combined with the continuing burden of
172 MPXV, this highlights the importance of further investigating the long-term efficacy of MVA-
173 BN. Ongoing circulation of clade I(b) MPXV in the Democratic Republic of the Congo [12]
174 necessitates future studies elaborating on the cross-reactivity of vaccine-induced antibody
175 responses against this circulating clade. In addition, administration of a booster dose one
176 year after the initial dose could be considered to improve vaccine immunogenicity [4, 6].
177 Taken together, our data contribute to the understanding of waning humoral immune
178 responses following MVA-BN vaccination, and support decision making on vaccination
179 strategies.

180 **Acknowledgments**

181 The authors thank the colleagues of the GGD Rotterdam-Rijnmond (Municipal Public Health
182 Service Rotterdam-Rijnmond, Rotterdam, the Netherlands) and the Travel Clinic Erasmus
183 MC who supported this study. We thank Denise Twisk (Municipal Public Health Service
184 Rotterdam-Rijnmond, Rotterdam, the Netherlands) for help with management of clinical data.
185 This project has received funding from the European Union's funding program H2020
186 research and innovation program under grant agreement 101115188 and the Netherlands
187 Organization for Health Research and Development (ZonMw) under grant agreement
188 10150022310035.

189

190 **Conflicts of interest**

191 No reported conflicts of interest.

192

193 **Author contributions**

194 Study conceptualization: LPMvL, MCS, BEV, HMG, ECMG, RDdV, CHGvK, LMZ.
195 Methodology: LPMvL, MCS, BEV, ECMG, RDdV, CHGvK, LMZ. Formal analysis: LPMvL,
196 MCS, BEV, RDdV, CHGvK, LMZ. Investigation: LPMvL, MCS, BEV, HMG, NA, KSS, KW,
197 SB, ECMG, RDdV, CHGvK, LMZ. Resources: HMG, MPGK, ECMvG, RDdV, CHGvK. Data
198 curation: LPMvL, MCS, BEV, ECMG, RDdV, CHGvK, LMZ. Project administration: LPMvL,
199 MCS, BEV, ECMG, RDdV, CHGvK, LMZ. Visualization: LPMvL, MCS, LMZ. Supervision:
200 ECMvG, RDdV, CHGvK, LMZ. Writing – original draft: LPMvL, MCS, BEV, RDdV, CHGvK,
201 LMZ. Writing – review and editing: All authors.

202

203 **References**

204

- 205 1. WHO. Multi-country outbreak of mpox. External Situation Report 33. Available at:
206 [https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-](https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-33--31-may-2024)
207 [situation-report-33--31-may-2024](https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-33--31-may-2024). Accessed 24-06-2024.
- 208 2. Berry MT, Khan SR, Schlub TE, et al. Predicting vaccine effectiveness for mpox. *Nat*
209 *Commun* **2024**; 15(1): 3856.
- 210 3. Hazra A, Zucker J, Bell E, et al. Mpox in people with past infection or a complete
211 vaccination course: a global case series. *Lancet Infect Dis* **2024**; 24(1): 57-64.
- 212 4. Zaeck LM, Lamers MM, Verstrepen BE, et al. Low levels of monkeypox virus
213 neutralizing antibodies after MVA-BN vaccination in healthy individuals. *Nat Med*
214 **2022**.
- 215 5. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists
216 for decades: a longitudinal study. *Am J Med* **2008**; 121(12): 1058-64.
- 217 6. Ilchmann H, Samy N, Reichhardt D, et al. One- and Two-Dose Vaccinations With
218 Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory
219 Responses Comparable to Replicating Smallpox Vaccines. *J Infect Dis* **2023**;
220 227(10): 1203-13.
- 221 7. Oom AL, Kottkamp AC, Wilson KK, et al. The Durability and Avidity of MPXV-specific
222 Antibodies Induced by the Two-dose MVA-BN Mpox Vaccine. *medRxiv* **2024**:
223 2024.01.28.24301893.
- 224 8. Moraes-Cardoso I, Benet S, Carabelli J, et al. Immune responses associated with
225 mpox viral clearance in men with and without HIV in Spain: a multisite, observational,
226 prospective cohort study. *Lancet Microbe* **2024**.
- 227 9. Priyamvada L, Carson WC, Ortega E, et al. Serological responses to the MVA-based
228 JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic
229 Republic of Congo. *Vaccine* **2022**; 40(50): 7321-7.
- 230 10. Crandell J, Monteiro VS, Pischel L, et al. The impact of antigenic distance on
231 Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity.
232 *medRxiv* **2024**: 2024.01.31.24302065.
- 233 11. Shamier MC, Zaeck LM, Götz HM, et al. Scenarios of future mpox outbreaks among
234 men who have sex with men: a modelling study based on cross-sectional
235 seroprevalence data from the Netherlands, 2022. *Euro Surveill* **2024**; 29(17).
- 236 12. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, et al. Sustained human outbreak of a
237 new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nat Med*
238 **2024**.

239 **Figure 1. Antibody longevity after MVA-BN vaccination.** VACV-specific binding or MVA
240 neutralizing antibodies (nAbs) were measured in sera obtained from two cohorts: **(A-D)**
241 COVA (individuals born from 1974 onwards are presumed to be immunologically naive,
242 those born before 1974 are presumed to have received historic smallpox vaccination); and
243 **(E-H)** RestPlus. **(A)** VACV-specific binding antibody levels in immunologically naive
244 participants (circles) after receiving two doses of MVA-BN. **(B)** VACV-specific binding
245 antibody levels in participants with pre-existing immunity (squares) after receiving either one
246 dose (blue) or two doses (gray) of MVA-BN. One participant born before 1974 deviated from
247 the study protocol and had a V1 instead of a V2 visit. **(C, D)** MVA nAbs in naive participants
248 **(C)** or participants with pre-existing immunity **(D)**, after receiving one (blue) or two doses
249 (gray) of MVA-BN. Data are shown in box-and-whisker plots, with the horizontal lines
250 indicating the median, the bounds of the boxes indicating the interquartile range (IQR), and
251 the whiskers indicating the range. Bold numbers above the plots represent the geometric
252 mean titer (GMT) per timepoint. Donut graphs show percentage of positive samples per
253 timepoint. **(E, F)** VACV-specific binding antibody levels in RestPlus participants without
254 detectable antibodies at baseline (BL-) after receiving either one **(E)** or two doses of MVA-
255 BN **(F)**. The red line represents a suspected infection. **(G)** VACV-specific binding antibody
256 levels in RestPlus participants with detectable antibodies at baseline (BL+) and either one
257 (gray line) or two doses (orange line) of MVA-BN. **(H)** VACV-specific binding antibody levels
258 in RestPlus participants with a PCR-confirmed MPXV infection. All individuals were
259 unvaccinated except for one (purple line). The blue line in **E-G** represents the 7-day rolling
260 GMT; V0=baseline; V1=14 days after first dose; V2=28 days after first dose; V3=28 days
261 after second dose; V4=1 year follow-up.

